Cruickshank, M N
Ford, J
Cheung, L C
Heng, J
Singh, S
Wells, J
Failes, T W
Arndt, G M
Smithers, N
Prinjha, R K
Anderson, D
Carter, K W
Gout, A M
Lassmann, T
O'Reilly, J
Cole, C H
Kotecha, R S
Kees, U R
Article History
Received: 23 December 2015
Revised: 5 May 2016
Accepted: 26 May 2016
First Online: 13 June 2016
Competing interests
: RK Prinjha and N Smithers are employees and shareholders of GlaxoSmithKline, which is carrying out clinical development of epigenetic inhibitors. The remaining authors declare no conflict of interest.